

Special Issue

Novel Biomarkers and Technologies in the Research and Diagnosis of Human Diseases

Message from the Guest Editor

Coincident with progress in basic and translational sciences, novel technologies, such as nucleic acid amplification tests, proteomics and next-generation sequencing, have been widely employed in the research, diagnosis and management of human diseases. These novel diagnostic and therapeutic techniques not only provide more sensitive and specific approaches to providing enhanced patient care, but also offer advanced tools with which to discover and study novel biomarkers (e.g., novel molecular targets, protein biomarkers and clinical indexes) in order to characterize the underlying mechanisms of pathogenesis, disease severity and prognosis. Notably, the emergence of novel technologies and biomarkers has led to more challenges and opportunities in the validation and verification of their clinical application, the thorough evaluation of their clinical utility, as well as the correlation between new and traditional biomarkers/techniques. This calls for a careful investigation of these topics and an improved R&D process in order to suitably utilize these novel biomarkers and technologies.

Guest Editor

Dr. Benjamin M. Liu

Departments of Pathology, Pediatrics, and Microbiology, Immunology & Tropical Medicine, Children's National Hospital, Washington, DC, USA

Deadline for manuscript submissions

closed (31 August 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/183306

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).